Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2002-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or sulphonylurea or repaglinide.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus

• Diet treated and/or subjects in monotherapy with sulphonylurea or repaglinide

• HbA1c for diet treated subjects 6.5-12%, both inclusive

• HbA1c for sulphonylurea or repaglinide treated subjects maximum 10%

• Body mass index (BMI) at least 27 kg/m^2

• Euthyroid subjects

• Fasting blood glucose 7-14 mmol/l

Exclusion Criteria:

• Impaired liver function

• Impaired renal function

• Cardiac problems

• Uncontrolled treated/untreated hypertension

• Recurrent severe hypoglycaemia as judged by the Investigator

• Known or suspected allergy to trial product or related products

• Use of any drug (except for OHAs (oral hypoglycaemic agents), which in the Investigator's opinion could interfere with the glucose level or body weight. Stable doses, for 3 months or greater, of thyroid hormone replacement are allowed